FRI0464 Long-Term Efficacy of Ustekinumab Treatment in Patients Affected by Psoriatic Arthritis Previously Treated with TNF Inhibitors

BackgroundIL12 and IL23 are two main cytokines involved in the pathogenesis of immune-mediated diseases. IL-12 is produced by macrophages and B lymphocytes and mediates differentiation of Th1 lymphocytes, while IL-23 is a pro-inflammatory cytokine essential for the differentiation of Th17 cells. Ustekinumab is a human monoclonal antibody directed against the p40 protein subunit shared by IL-12 and IL-23, blocking the signal transmission of both cytokines involved in the pathogenesis of both Psoriasis (PsO) and Psoriatic Arthritis (PsA)ObjectivesEvaluate the long-term efficacy of treatment with Ustekinumab in PsA patients previously treated with TNF inhibitors (TNF-i) in real lifeMethodsWe prospectively evaluated patients with PsO and moderate-severe PsA, who were treated with Ustekinumab after the failure of previous TNF-i therapies, in the period January 2013 -December 2015. Clinimetric scores (PASI, DAS44CRP, Pain VAS, Clinicians' VAS, and HAQ) were assessed and biochemical values (ESR, CRP, glucose, cholesterol, uric acid) were measured at baseline (T0) and after 6 (T6), 12 (T12) and 24 (T24) months. Differences between variables were analysed with paired T test (P